A role for neoadjuvant gemcitabine plus cisplatin in muscle-invasive urothelial carcinoma of the bladder: A retrospective experience

Cancer

Volumn 113, Issue 9, 2008, Pages 2471-2477

  Dash, Atreya ^a,b   Pettus IV, Joseph A ^a,b   Herr, Harry W ^a,b   Bochner, Bernard H ^a,b   Dalbagni, Guido ^a,b   Donat, S Machele ^a,b   Russo, Paul ^a,b   Boyle, Mary G ^a,b   Milowsky, Matthew I ^a,b   Bajorin, Dean F ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Chemotherapy; Cisplatin; Neoadjuvant; Radical cystectomy; Urothelial carcinoma

Indexed keywords

CISPLATIN; DOXORUBICIN; GEMCITABINE; METHOTREXATE; VINBLASTINE;

ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BLADDER CARCINOMA; BLADDER DISEASE; CONTROLLED STUDY; CYSTECTOMY; DEHYDRATION; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYPOTENSION; INVASIVE CARCINOMA; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALE; MULTIPLE CYCLE TREATMENT; PELVIS LYMPHADENECTOMY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SMALL CELL CARCINOMA; THROMBOEMBOLISM; TRANSITIONAL CELL CARCINOMA; TREATMENT OUTCOME; UROTHELIUM; VOMITING;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, TRANSITIONAL CELL; CHEMOTHERAPY, ADJUVANT; CISPLATIN; CYSTECTOMY; DEOXYCYTIDINE; DISEASE-FREE SURVIVAL; FEASIBILITY STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE NEOPLASMS; NEOADJUVANT THERAPY; NEOPLASM INVASIVENESS; RETROSPECTIVE STUDIES; SURVIVAL RATE; URINARY BLADDER NEOPLASMS;

EID: 55549148741     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.23848     Document Type: Article

References (20)

1. Stein JP, Lieskovsky G, Cote R, et al. Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol. 2001;19:666-675.
2. Advanced Bladder Cancer (ABC) Meta-analysis Collaboration. Neoadjuvant chemotherapy in invasive bladder cancer: update of a systematic review and metaanalysis of individual patient data. Eur Urol. 2005;48:202-205.
3. Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. J Clin Oncol. 1992;10:1066-1073.
4. Grossman HB, Natale RB, Tangen CM, et al. Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer. N Engl J Med. 2003;349:859-866.
5. David KA, Milowsky MI, Ritchey J, et al. Low incidence of perioperative chemotherapy for stage III bladder cancer 1998-2003: a report from the national cancer data base. J Urol. 2007; 178:451-454.
6. Mamhmud S, Fong B, Fahmy N, et al. Effect of preoperative delay on survival in patients with bladder cancer undergoing cystectomy in Quebec: a population based study. J Urol. 2006;175:78-83.
7. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized multicenter, multinational multicenter, phase III study. J Clin Oncol. 2000;18:3068-3077.
8. von der Maase H, Sengelov L, Roberts JT, et al. Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer. J Clin Oncol. 2005;23:4602-4608.
9. Dienstmann R, Herchenhorn D, Peixoto F, et al. Phase II trial of gemcitabine and cisplatin as neoadjuvant chemotherapy for invasive bladder cancer: preliminary results [abstract]. J Clin Oncol. 2006;24(suppl):644S. Abstract 14590.
10. Dogliotti L, Carteni G, Siena S, et al. Gemcitabine plus cisplatin versus gemcitabine plus carboplatin as first-line chemotherapy in advanced transitional cell carcinoma of the urothelium: results of a randomized phase II trial. Eur Urol. 2007;52:134-141.
11. Soto Parra H, Cavina R, Latteri F, et al. Three-week versus 4-week schedule of cisplatin and gemcitabine: results of a randomized phase II study. Ann Oncol. 2002;13:1080-1086.
12. Rinaldi M, Crino L, Scagliotti G, et al. A 3-week schedule of gemcitabine-cisplatin in advanced non-small-cell lung cancer with 2 different cisplatin dose levels: a phase II randomized trial. Ann Oncol. 2000;11:1295-1300.
13. Hussain S, Stocken D, Riley P, et al. A phase I/II study of gemcitabine and fractionated cisplatin in an outpatient setting using a 21-day schedule in patients with advanced and metastatic bladder cancer. Br J Cancer. 2004;91:844-849.
14. Schultz PK, Herr HW, Zhang ZF, et al. Neoadjuvant chemotherapy for invasive bladder cancer: prognostic factors for survival of patients treated with M-VAC with 5-year followup. J Clin Oncol. 1994;12:1394-1401.
15. Dodd PM, McCaffrey JA, Mazumdar M, et al. Evaluation of drug delivery and survival impact of dose-intense relative to conventional-dose methotrexate, vinblastine, doxorubicin, and cisplatin chemotherapy in urothelial cancer. Cancer Invest. 2000;18:626-634.
16. Splinter TA, Scher HI, Denis L, et al. The prognostic value of the pathological response to combination chemotherapy before cystectomy in patients with invasive bladder cancer. European Organization for Research on Treatment of Cancer-Genitourinary Group. J Urol. 1992; 147:606-608.
17. Hall RR, on behalf of the International Collaboration of Trialists of the MRC Advanced Bladder Cancer Group, MRC Clinical Trials Unit, London, UK. Updated results of a randomised controlled trial of neoadjuvant cisplatin (C), methotrexate (M) and vinblastine (V) chemotherapy for muscle-invasive bladder cancer [abstract]. Proc Am Soc Clin Oncol. 2002;21:178A. Abstract 710.
18. Neoadjuvant cisplatin, methotrexate and vinblastine chemotherapy for muscle-invasive bladder cancer: a randomised controlled trial. International collaboration of trialists. Lancet. 1999;354:533-540.
19. Winquist E, Wilson J, Dorreen M, et al. A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer. Can J Urol. 2004;11:2445-2449.
20. Czaykowski P, Moore M, Tannock I. High risk of vascular events in patients with urothelial transitional cell carcinoma treated with cisplatin based chemotherapy. J Urol. 1998;160:2021-2024.